CYTOF Quote, Financials, Valuation and Earnings

CEL-SCI has a net margin of -- compared to Altamira Therapeutics's net margin of --. Altamira Therapeutics's return on equity of -- beat CEL-SCI's return on equity of --.

Altamira Therapeutics has a consensus price target of --, signalling upside risk potential of 4364.98%. On the other hand CEL-SCI has an analysts' consensus of -- which suggests that it could grow by 959.51%. Given that Altamira Therapeutics has higher upside potential than CEL-SCI, analysts believe Altamira Therapeutics is more attractive than CEL-SCI.

Altamira Therapeutics has a beta of 2.426, which suggesting that the stock is 142.617% more volatile than S&P 500. In comparison CEL-SCI has a beta of 0.593, suggesting its less volatile than the S&P 500 by 40.711%.

Altamira Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altamira Therapeutics pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

Altamira Therapeutics quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. Altamira Therapeutics's net income of -- is lower than CEL-SCI's net income of -$6.9M. Notably, Altamira Therapeutics's price-to-earnings ratio is 0.25x while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altamira Therapeutics is -- versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma has a net margin of -- compared to Altamira Therapeutics's net margin of -416.75%. Altamira Therapeutics's return on equity of -- beat IGC Pharma's return on equity of -137.43%.

Altamira Therapeutics has a consensus price target of --, signalling upside risk potential of 4364.98%. On the other hand IGC Pharma has an analysts' consensus of -- which suggests that it could grow by 889.45%. Given that Altamira Therapeutics has higher upside potential than IGC Pharma, analysts believe Altamira Therapeutics is more attractive than IGC Pharma.

Altamira Therapeutics has a beta of 2.426, which suggesting that the stock is 142.617% more volatile than S&P 500. In comparison IGC Pharma has a beta of 1.288, suggesting its more volatile than the S&P 500 by 28.8%.

Altamira Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altamira Therapeutics pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

Altamira Therapeutics quarterly revenues are --, which are smaller than IGC Pharma quarterly revenues of $412K. Altamira Therapeutics's net income of -- is lower than IGC Pharma's net income of -$1.7M. Notably, Altamira Therapeutics's price-to-earnings ratio is 0.25x while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altamira Therapeutics is -- versus 22.17x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Kiniksa Pharmaceuticals International PLC has a net margin of -- compared to Altamira Therapeutics's net margin of -11.31%. Altamira Therapeutics's return on equity of -- beat Kiniksa Pharmaceuticals International PLC's return on equity of -2.11%.

Altamira Therapeutics has a consensus price target of --, signalling upside risk potential of 4364.98%. On the other hand Kiniksa Pharmaceuticals International PLC has an analysts' consensus of -- which suggests that it could grow by 74.84%. Given that Altamira Therapeutics has higher upside potential than Kiniksa Pharmaceuticals International PLC, analysts believe Altamira Therapeutics is more attractive than Kiniksa Pharmaceuticals International PLC.

Altamira Therapeutics has a beta of 2.426, which suggesting that the stock is 142.617% more volatile than S&P 500. In comparison Kiniksa Pharmaceuticals International PLC has a beta of 0.268, suggesting its less volatile than the S&P 500 by 73.21%.

Altamira Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kiniksa Pharmaceuticals International PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altamira Therapeutics pays -- of its earnings as a dividend. Kiniksa Pharmaceuticals International PLC pays out -- of its earnings as a dividend.

Altamira Therapeutics quarterly revenues are --, which are smaller than Kiniksa Pharmaceuticals International PLC quarterly revenues of $112.2M. Altamira Therapeutics's net income of -- is lower than Kiniksa Pharmaceuticals International PLC's net income of -$12.7M. Notably, Altamira Therapeutics's price-to-earnings ratio is 0.25x while Kiniksa Pharmaceuticals International PLC's PE ratio is 153.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altamira Therapeutics is -- versus 3.90x for Kiniksa Pharmaceuticals International PLC. Usually stocks with elevated PS ratios are considered overvalued.

Tiziana Life Sciences has a net margin of -- compared to Altamira Therapeutics's net margin of --. Altamira Therapeutics's return on equity of -- beat Tiziana Life Sciences's return on equity of --.

Altamira Therapeutics has a consensus price target of --, signalling upside risk potential of 4364.98%. On the other hand Tiziana Life Sciences has an analysts' consensus of -- which suggests that it could grow by 287.09%. Given that Altamira Therapeutics has higher upside potential than Tiziana Life Sciences, analysts believe Altamira Therapeutics is more attractive than Tiziana Life Sciences.

Altamira Therapeutics has a beta of 2.426, which suggesting that the stock is 142.617% more volatile than S&P 500. In comparison Tiziana Life Sciences has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.656%.

Altamira Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tiziana Life Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altamira Therapeutics pays -- of its earnings as a dividend. Tiziana Life Sciences pays out -- of its earnings as a dividend.

Altamira Therapeutics quarterly revenues are --, which are smaller than Tiziana Life Sciences quarterly revenues of --. Altamira Therapeutics's net income of -- is lower than Tiziana Life Sciences's net income of --. Notably, Altamira Therapeutics's price-to-earnings ratio is 0.25x while Tiziana Life Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altamira Therapeutics is -- versus 1,374.78x for Tiziana Life Sciences. Usually stocks with elevated PS ratios are considered overvalued.